Medical Research
(H99)
IRS Verified
DX Registered
990 on File
BLAST GLIOBLASTOMA
Financial strength (30%)
49/100
Reliability (20%)
50/100
Effectiveness (25%)
48/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2024
$9K
Total Revenue
$388
Total Expenses
$122K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
0.0%
Fundraising Efficiency
N/A
Operating Reserve
3784.45x
Liability-to-Asset
0.0%
Revenue Diversification
62.6%
Compared with Peers
FY 2024
Compared with 782 similar organizations
(United States, Medical Research, under $100K in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
0.0% | 78.0% |
P10P90
|
Bottom quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
100.0% | 12.2% |
P10P90
|
Bottom quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
3784.5 mo | 38.9 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
62.6% | 100.0% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
-87.5% | -0.9% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
139.5% | -6.4% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
95.5% | 15.4% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $9K | $388 | $122K | 0.0% | 0 |
| 2023 | $68K | $162 | $114K | 0.0% | 0 |
| 2022 | $8K | $750K | $46K | 100.0% | 0 |
| 2021 | $7K | $583 | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.